---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010097"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T11:26:08.752860+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech Q1 revenue up 26% to $23.4M; net loss widens to $3.5M

## Summary
- Net revenue $23.4M (+26% YoY); net loss $3.5M vs $1.8M loss in Q1 2024.
- Adjusted EBITDA improved to $0.7M from $0.3M; gross margin 92% vs 90%.
- Sanara Surgical revenue drove growth; segment net loss $0.6M; Tissue Health Plus loss $2.9M.
- Borrowed $12.25M under amended CRG term loan; $12.25M additional available through Dec 2025.
- Appointed Elizabeth Taylor CFO; exclusive BMI license for OsStic bone void filler and ARC technology.

## SEC filing metadata
- accession: 0001641172-25-010097
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000164117225010097/0001641172-25-010097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000164117225010097/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010097
- JSON: https://secwatch.observer/filing/0001641172-25-010097.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.